



## Rubius Therapeutics to Announce Third Quarter 2020 Financial Results

October 29, 2020

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced plans to report third quarter 2020 financial results on Monday, November 9, 2020, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

### About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics' manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit [www.rubiustx.com](http://www.rubiustx.com), follow us on [Twitter](#) or [LinkedIn](#) or like us on [Facebook](#).

### Contacts:

Lori Melançon  
Vice President, Corporate Communications and Investor Relations  
+1 (617) 949-5296  
[lori.melancon@rubiustx.com](mailto:lori.melancon@rubiustx.com)

### Media:

Marissa Hanify  
Director, Corporate Communications  
[marissa.hanify@rubiustx.com](mailto:marissa.hanify@rubiustx.com)

Dan Budwick  
1AB  
+1 (973) 271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)



Source: Rubius Therapeutics